SK1012004A3 - Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka - Google Patents

Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka Download PDF

Info

Publication number: SK1012004A3
Authority: SK; Slovakia
Prior art keywords: azithromycin; dose; medicament; treatment; range
Prior art date: 2001-08-21

Application number

SK101-2004A

Other languages

English (en)

Slovak (sk)

Inventor

Michael William Dunne

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-21

Filing date

2002-07-31

Publication date

2005-04-01

2002-07-31 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-04-01 Publication of SK1012004A3 publication Critical patent/SK1012004A3/sk

Links

229960004099 azithromycin Drugs 0.000 title claims abstract description 46
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 46
206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 17
239000003814 drug Substances 0.000 title claims description 15
238000004519 manufacturing process Methods 0.000 title claims description 8
230000037396 body weight Effects 0.000 claims description 13
208000022760 infectious otitis media Diseases 0.000 claims description 10
239000007788 liquid Substances 0.000 claims description 5
108090000623 proteins and genes Proteins 0.000 claims description 4
238000000034 method Methods 0.000 abstract description 8
208000015181 infectious disease Diseases 0.000 description 16
244000052769 pathogen Species 0.000 description 10
241000606768 Haemophilus influenzae Species 0.000 description 8
208000005141 Otitis Diseases 0.000 description 6
208000019258 ear infection Diseases 0.000 description 6
230000001154 acute effect Effects 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
241000699694 Gerbillinae Species 0.000 description 4
241000588655 Moraxella catarrhalis Species 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
206010033078 Otitis media Diseases 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
241000194032 Enterococcus faecalis Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000193996 Streptococcus pyogenes Species 0.000 description 2
238000011161 development Methods 0.000 description 2
210000000959 ear middle Anatomy 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000008029 eradication Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
210000003454 tympanic membrane Anatomy 0.000 description 2
VQEMDSRIOVZAOM-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CSC(N)=N1 VQEMDSRIOVZAOM-UHFFFAOYSA-N 0.000 description 1
101150076489 B gene Proteins 0.000 description 1
206010008326 Cervicitis gonococcal Diseases 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
229930006677 Erythromycin A Natural products 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010040007 Sense of oppression Diseases 0.000 description 1
201000010439 acute gonococcal cervicitis Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229960004924 azithromycin dihydrate Drugs 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000032625 disorder of ear Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000028320 gonococcal cervicitis Diseases 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

SK101-2004A 2001-08-21 2002-07-31 Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka SK1012004A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31386701P	2001-08-21	2001-08-21
PCT/IB2002/003076 WO2003018031A2 (fr)	2001-08-21	2002-07-31	Azithromycine unidose

Publications (1)

Publication Number	Publication Date
SK1012004A3 true SK1012004A3 (sk)	2005-04-01

Family

ID=23217490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK101-2004A SK1012004A3 (sk)	2001-08-21	2002-07-31	Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka

Country Status (25)

Country	Link
US (3)	US20030148964A1 (fr)
EP (1)	EP1418924A2 (fr)
JP (1)	JP2005501862A (fr)
KR (1)	KR20040032942A (fr)
AP (1)	AP1729A (fr)
BG (1)	BG108537A (fr)
BR (1)	BR0211830A (fr)
CA (1)	CA2458135A1 (fr)
CZ (1)	CZ2004232A3 (fr)
EA (1)	EA200400214A1 (fr)
EC (1)	ECSP044985A (fr)
GE (1)	GEP20063812B (fr)
HR (1)	HRP20040163A2 (fr)
HU (1)	HUP0401332A2 (fr)
IL (1)	IL159585A0 (fr)
IS (1)	IS7092A (fr)
MA (1)	MA27059A1 (fr)
MX (1)	MXPA04001605A (fr)
OA (1)	OA12845A (fr)
PL (1)	PL367888A1 (fr)
SK (1)	SK1012004A3 (fr)
TN (1)	TNSN04035A1 (fr)
WO (1)	WO2003018031A2 (fr)
YU (1)	YU8804A (fr)
ZA (1)	ZA200400804B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005009447A1 (fr) *	2003-07-24	2005-02-03	Pliva - Research And Development Ltd.	Dose unique a dissolution rapide d'azithromycine
US6984403B2 (en)	2003-12-04	2006-01-10	Pfizer Inc.	Azithromycin dosage forms with reduced side effects
CA2549225A1 (fr)	2003-12-04	2005-06-16	Pfizer Products Inc.	Procede d'atomisation/congelation faisant appel a une extrudeuse pour la preparation de compositions medicamenteuses cristallines multiparticulaires contenant de preference un poloxamere et un glyceride
JP2007513145A (ja)	2003-12-04	2007-05-24	ファイザー・プロダクツ・インク	医薬用多微粒子の製造方法
JP2007513139A (ja)	2003-12-04	2007-05-24	ファイザー・プロダクツ・インク	安定性の改善した多粒子組成物
US20060116336A1 (en) *	2004-03-17	2006-06-01	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
US7468428B2 (en)	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
JP5324223B2 (ja)	2005-12-08	2013-10-23	トランセイブ，インク．	肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
US9119783B2 (en)	2007-05-07	2015-09-01	Insmed Incorporated	Method of treating pulmonary disorders with liposomal amikacin formulations
US20090005326A1 (en) *	2007-06-26	2009-01-01	Idexx Laboratories, Inc.	Single dose roxithromycin
US20090197956A1 (en) *	2008-02-04	2009-08-06	Arbor Pharmaceuticals, Inc.	Treatment of acute otitis media with xylitol and n-acetylcysteine
WO2009114810A2 (fr) *	2008-03-14	2009-09-17	The Florida International Uinversity Board Of Trustees	Utilisation d'ellagitannines comme inhibiteurs de la détection du quorum bactérien
US20130156803A1 (en)	2011-06-04	2013-06-20	Rochester General Hospital Research Institute	Compositions and methods related to p6
MX2015006681A (es)	2012-11-29	2016-04-06	Insmed Inc	Formulaciones de vancomicina estabilizadas.
SMT202000516T1 (it)	2014-05-15	2020-11-10	Insmed Inc	Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
WO2019191627A1 (fr)	2018-03-30	2019-10-03	Insmed Incorporated	Procédés pour la fabrication continue de produits médicamenteux liposomaux
WO2019213398A1 (fr)	2018-05-02	2019-11-07	Insmed Incorporated	Procédés de fabrication de formulations de médicament liposomal
WO2021163451A1 (fr) *	2020-02-14	2021-08-19	Asklepios Biopharmaceutical, Inc.	Procédé de traitement d'une toxicité associée à une thérapie génique avec des antibiotiques

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US53264A (en) *		1866-03-20		Improved ditching-machine
SI7910768A8 (en) *	1979-04-02	1996-06-30	Pliva Pharm & Chem Works	Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
SI8110592A8 (en) *	1981-03-06	1996-06-30	Pliva Pharm & Chem Works	Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) *	1987-07-09	1993-10-30	Pfizer	Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (fr) *	1987-09-10	1989-03-23	Pfizer	Azithromycine et derives utilises comme agents anti-protozoaires
YU45590A (sh) *	1990-03-07	1992-07-20	PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o.	Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
TW271400B (fr) *	1992-07-30	1996-03-01	Pfizer
ES2104386T3 (es) *	1993-05-19	1997-10-01	Pfizer	Compuesto intermedio para la acitromicina.
US5605889A (en) *	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
EP0758244B2 (fr) *	1994-05-06	2008-02-13	Pfizer Inc.	Formes galeniques a liberation controlee de l'azithromycine
HRP980189B1 (en) *	1998-04-06	2004-04-30	Pliva Pharm & Chem Works	Novel 15-membered lactams ketolides
US6239113B1 (en) *	1999-03-31	2001-05-29	Insite Vision, Incorporated	Topical treatment or prevention of ocular infections
US20040053264A1 (en) *	2002-02-01	2004-03-18	Park Sung Sup	Clinical panel assay using DNA chips

2002
- 2002-07-31 HR HR20040163A patent/HRP20040163A2/xx not_active Application Discontinuation
- 2002-07-31 SK SK101-2004A patent/SK1012004A3/sk not_active Application Discontinuation
- 2002-07-31 IL IL15958502A patent/IL159585A0/xx unknown
- 2002-07-31 HU HU0401332A patent/HUP0401332A2/hu unknown
- 2002-07-31 YU YU8804A patent/YU8804A/sh unknown
- 2002-07-31 PL PL02367888A patent/PL367888A1/xx not_active Application Discontinuation
- 2002-07-31 JP JP2003522549A patent/JP2005501862A/ja active Pending
- 2002-07-31 AP APAP/P/2004/002968A patent/AP1729A/en active
- 2002-07-31 CZ CZ2004232A patent/CZ2004232A3/cs unknown
- 2002-07-31 WO PCT/IB2002/003076 patent/WO2003018031A2/fr not_active Ceased
- 2002-07-31 GE GE5411A patent/GEP20063812B/en unknown
- 2002-07-31 MX MXPA04001605A patent/MXPA04001605A/es active IP Right Grant
- 2002-07-31 EP EP02753170A patent/EP1418924A2/fr not_active Withdrawn
- 2002-07-31 EA EA200400214A patent/EA200400214A1/ru unknown
- 2002-07-31 CA CA002458135A patent/CA2458135A1/fr not_active Abandoned
- 2002-07-31 BR BR0211830-0A patent/BR0211830A/pt not_active IP Right Cessation
- 2002-07-31 KR KR10-2004-7002492A patent/KR20040032942A/ko not_active Ceased
- 2002-07-31 OA OA1200400048A patent/OA12845A/en unknown
- 2002-08-21 US US10/224,903 patent/US20030148964A1/en not_active Abandoned
2003
- 2003-07-25 US US10/628,102 patent/US6987093B2/en not_active Expired - Fee Related
- 2003-12-23 IS IS7092A patent/IS7092A/is unknown
2004
- 2004-01-21 BG BG108537A patent/BG108537A/bg unknown
- 2004-01-30 ZA ZA200400804A patent/ZA200400804B/en unknown
- 2004-02-11 MA MA27523A patent/MA27059A1/fr unknown
- 2004-02-20 EC EC2004004985A patent/ECSP044985A/es unknown
- 2004-02-20 TN TNP2004000035A patent/TNSN04035A1/fr unknown
2005
- 2005-06-29 US US11/172,012 patent/US7067493B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IS7092A (is)	2003-12-23
EP1418924A2 (fr)	2004-05-19
US20040023898A1 (en)	2004-02-05
ECSP044985A (es)	2004-04-28
JP2005501862A (ja)	2005-01-20
WO2003018031A3 (fr)	2003-10-02
MA27059A1 (fr)	2004-12-20
US7067493B2 (en)	2006-06-27
AP2004002968A0 (en)	2004-03-31
EA200400214A1 (ru)	2004-06-24
HUP0401332A2 (hu)	2004-11-29
IL159585A0 (en)	2004-06-01
MXPA04001605A (es)	2004-07-08
OA12845A (en)	2006-09-15
US20030148964A1 (en)	2003-08-07
ZA200400804B (en)	2005-05-03
CA2458135A1 (fr)	2003-03-06
AP1729A (en)	2007-03-26
WO2003018031A2 (fr)	2003-03-06
CZ2004232A3 (cs)	2005-10-12
GEP20063812B (en)	2006-05-10
YU8804A (sh)	2006-08-17
HRP20040163A2 (en)	2005-02-28
US6987093B2 (en)	2006-01-17
BG108537A (bg)	2005-02-28
PL367888A1 (en)	2005-03-07
BR0211830A (pt)	2004-09-08
KR20040032942A (ko)	2004-04-17
US20050250712A1 (en)	2005-11-10
TNSN04035A1 (fr)	2006-06-01

Legal Events

Date	Code	Title	Description
2010-11-08	FC9A	Refused patent application

Publication	Publication Date	Title
Biondi et al.	1997	Psychological stress, neuroimmunomodulation, and susceptibility to infectious diseases in animals and man: a review
CZ2004232A3 (cs)	2005-10-12	Jednorázová dávka azithromycinu
Imran et al.	2021	Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
Henley et al.	1993	Developmental ototoxicity
Li et al.	2003	A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China
CN118021821A (zh)	2024-05-14	治疗、预防由病毒感染引起的相关疾病的药物及其用途
US20230111504A1 (en)	2023-04-13	Coronaviridae infection and avermectins
CN1342081A (zh)	2002-03-27	用于治疗由肉孢子虫、新孢子虫和弓形虫引起的疾病的三嗪酮化合物
US20200330487A1 (en)	2020-10-22	Prevention and treatment of flu-type viral infections and related complications
Channa et al.	2006	Effect of ciprofoxacin on growing cartilage in albino rat pups
US11090315B1 (en)	2021-08-17	Prevention and treatment of flu-type viral infections and related complications
AU2002313574A1 (en)	2003-03-10	Single dose azithromycin for treating respiratory infections
US20230030607A1 (en)	2023-02-02	Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases
US20060142254A1 (en)	2006-06-29	Antipyretic preparation containing xylitol
US20060210483A1 (en)	2006-09-21	Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20250120929A1 (en)	2025-04-17	Method of treating virus-associated infection using acetaminophen
AU2023397177A1 (en)	2025-06-26	Solid dosage form of a small molecule antiviral and uses thereof
Güris	2000	Treatment and chemoprophylaxis
WO2023052830A2 (fr)	2023-04-06	Prévention et traitement d'infections virales de type grippe et de complications associées
HK40114059A (zh)	2025-02-28	α-1062用於治疗创伤性脑损伤
O'Horo	2020	Azithromycin
JP2024507417A (ja)	2024-02-19	イヌパルボウイルス感染を治療するための組成物および方法
Selliah et al.	2004	Pharmacokinetics of cationic liposome-encapsulated doxycycline in mice challenged with genital infection by Chlamydia trachomatis
Singh et al.	1995	Albendazole therapy in liver hydatidosis
Woods	2002	New threat from an ancient microbe: Anthrax